7

Over the past twenty-five years, there has been growing interest in the use of cannabis and cannabinoids for therapeutic purposes to treat various conditions including chronic pain, cancer pain, and neurological disorders. Most European countries now authorize their use in certain forms and under regulatory conditions that vary from one country to another. In 2014, a European Marketing Authorization was granted to a combination of CBD and THC to treat spastic pain linked to multiple sclerosis (MS), in addition to conventional drugs when these prove to be insufficiently effective. In France, the HAS (Haute Autorité de Santé [French National Health Authority]) has ruled in favor of reimbursement for epilepsies resistant to the treatment of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in patients aged two and over. What do the scientific studies say?